The purpose of this study is to understand how your gut plays a role in how well CAR T cell therapy works. Your gut is home to bacteria, which we call the gut microbiome. The gut microbiome can send signals to your immune cells, which may impact how well and how long CAR T cell therapy will last. We can find out what type of bacteria are in your gut microbiome by studying your stool. We can understand more about the signals sent to the immune system by studying your blood. We will ask for stool and blood at the same time points throughout your treatment. We will study the identities and function of the bacteria and immune cells to understand more about how these signals work during CAR T cell treatment.

To create digital tools to support young adult cancer survivors completing active treatment and transitioning into survivorship care.

This phase 3 trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs that work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will

This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.

Better understand symptoms that occur after liver-directed treatments for liver cancer

The purpose of this study is to develop a prospective longitudinal cohort/registry of lymphoma patients in Malawi to address a lack of prospective longitudinal data related to lymphoma in sub-Saharan Africa, and to serve as a foundation for developing optimal treatment strategies in this challenging environment.

This study is being conduced to assess the feasibility of conducting multi-center prospective studies on surgical excision of suspected OSSN lesions in SSA in people living with HIV/AIDS (PLWHA).

The purpose of this research study is to assess the patient-level, healthcare provider/system-level, and community-level barriers to resolving abnormal mammograms and initiation of treatment of breast cancer in the 3 geographic regions of North Carolina: the greater Charlotte area, the Northwest, and the Northeast. These areas include the following counties: Anson, Cabarrus, Cleveland, Gaston, Lincoln, Mecklenburg, Stanly, Union, Edgecombe, Halifax, Nash, Northampton, Wilson , Ashe, Alleghany, Surry, Stokes, Watauga, Wilkes, Yadkin, Forsyth, Avery, Caldwell, Alexander, Iredell, Davie, Davidson, Burke, Catawba, and Rowan. These barriers can include obtainment of biopsies and other diagnostic procedures for resolving abnormal mammograms abnormalities or breast symptoms, access to care providers after breast cancer diagnosis, and initiation of appropriate surgical, chemotherapy, and radiation treatments after diagnosis.

The GET SET Study is a research study for women who take medicines to help keep breast cancer from coming back. These medicines are called endocrine therapies and include Tamoxifen and Arimidex. The study will test different kinds of extra support programs, such as daily text message reminders and telephone counseling sessions, for women taking these medicines. We want to learn which support programs help women take their medicine as it is prescribed by their doctor.

We will identify changes in the numbers, seriousness, and outcomes of breast cancers diagnosed during the COVID-19 pandemic, compared to before the pandemic.